Health Canada is currently reviewing nine submissions for generic versions of popular obesity medications, potentially paving the way for lower prices this summer. The focus is...
Novo Nordisk announced on March 4, 2024, that its clinical trials for an oral version of the Alzheimer’s drug semaglutide did not succeed in slowing the...
Novo Nordisk has announced significant price reductions for its obesity treatments, Wegovy and Ozempic, in an effort to compete more effectively against rival Eli Lilly, which...
Recent research from the University of Utah has unveiled a promising method for enhancing glucagon-like peptide-1 (GLP-1) agonists, potentially paving the way for a new generation...
